These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33300880)

  • 41. T helper 17 cell/regulatory T-cell imbalance in hidradenitis suppurativa/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities.
    Melnik BC; John SM; Chen W; Plewig G
    Br J Dermatol; 2018 Aug; 179(2):260-272. PubMed ID: 29573406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
    Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
    Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of hair removal efficacy and side effect of neodymium:Yttrium-aluminum-garnet laser and intense pulsed light systems (18-month follow-up).
    Szima GZ; Janka EA; Kovács A; Bortély B; Bodnár E; Sawhney I; Szabó É; Remenyik É
    J Cosmet Dermatol; 2017 Jun; 16(2):193-198. PubMed ID: 28164458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hidradenitis Suppurativa in prepubescent and pubescent children.
    Scheinfeld N
    Clin Dermatol; 2015; 33(3):316-9. PubMed ID: 25889132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photoepilation with a diode laser vs. intense pulsed light: a randomized, intrapatient left-to-right trial.
    Klein A; Steinert S; Baeumler W; Landthaler M; Babilas P
    Br J Dermatol; 2013 Jun; 168(6):1287-93. PubMed ID: 23278132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions.
    Prussick L; Tonelli S; Gottlieb AB; Joshipura D; Alomran A; Zancanaro P; Courtney Kachuk RN; Dumont N; Rosmarin D
    J Dermatolog Treat; 2019 Nov; 30(7):708-713. PubMed ID: 30582391
    [No Abstract]   [Full Text] [Related]  

  • 50. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.
    Fotiadou C; Vakirlis E; Ioannides D
    Clin Cosmet Investig Dermatol; 2016; 9():367-372. PubMed ID: 27799806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-pharmacologic approaches for hidradenitis suppurativa - a systematic review.
    Hendricks AJ; Hirt PA; Sekhon S; Vaughn AR; Lev-Tov HA; Hsiao JL; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):11-18. PubMed ID: 31106609
    [No Abstract]   [Full Text] [Related]  

  • 52. Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa.
    James JF; Madray VM; Salame N; Hasan SB; White MS; Barron JR; Kirby J; Ingram JR; Orenstein LAV
    Dermatology; 2023; 239(1):45-51. PubMed ID: 36108592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Efficacy of Intense Pulsed Light With Radiofrequency in United States Hidradenitis Suppurativa Patients.
    Lyons A; Narla S; Kohli I; Zubair R; Jacobsen G; Ceresnie M; Parks-Miller A; Hamzavi I
    J Drugs Dermatol; 2022 Apr; 21(4):430-432. PubMed ID: 35389583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
    Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
    Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients.
    Krajewski PK; Matusiak Ł; von Stebut E; Schultheis M; Kirschner U; Nikolakis G; Szepietowski JC
    Acta Derm Venereol; 2021 Jan; 101(1):adv00364. PubMed ID: 33320274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa/Acne Inversa.
    Hunger RE; Laffitte E; Läuchli S; Mainetti C; Mühlstädt M; Schiller P; Lapointe AK; Meschberger P; Navarini AA
    Dermatology; 2017; 233(2-3):113-119. PubMed ID: 28683447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy.
    Vural S; Gündoğdu M; Akay BN; Boyvat A; Erdem C; Koçyiğit P; Bostancı S; Sanli H; Kundakci N
    Dermatol Ther; 2019 Sep; 32(5):e13003. PubMed ID: 31237104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update on the pathogenesis of hidradenitis suppurativa: implications for therapy.
    Negus D; Ahn C; Huang W
    Expert Rev Clin Immunol; 2018 Apr; 14(4):275-283. PubMed ID: 29509041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnosis and management of hidradenitis suppurativa in women.
    Collier EK; Parvataneni RK; Lowes MA; Naik HB; Okun M; Shi VY; Hsiao JL
    Am J Obstet Gynecol; 2021 Jan; 224(1):54-61. PubMed ID: 32980357
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.